News You Can Use
Updates and news related to prostate cancer:
Older Men Increasingly Overtreated for Prostate Cancer
VA analysis finds men with limited life expectancy still getting aggressive treatment.
Survival, Progression Improves With Xofigo Plus Xtandi for Certain Patients With Prostate Cancer
Patients with metastatic, castration-resistant prostate cancer saw significant benefits from the combination of Xofigo and Xtandi.
PSMA-PET by PROMISE Criteria Shows Prognostic Value Across Prostate Cancer Continuum
PPP nomograms accurately stratify high- vs. low-risk groups for overall survival in early and late stages of prostate cancer and yield better prediction than established clinical risk tools.
A Common Culprit Drives Prostate Cancer Progression
Activation of the MYC gene in prostate cancer leads to major changes in the surrounding microenvironment.
Neoadjuvant Exercise Therapy in Prostate Cancer
Observational data have shown that postdiagnosis exercise is associated with reduced risk of prostate cancer death.
Ancient Viruses Might Be Spurring Modern-Day Cancers
Cancer growth can be fueled by flecks of ancient viral DNA lodged into the genetics of modern humans, a new study says.
Study Reveals New AI Tool Predicts Recurrence of Prostate Cancer by a Decade
The study found genetic divergence and artificial intelligence-measured morphological diversity indicated the tumour’s ability to evolve to allow the disease to adapt and survive.
AI Tool Detects Prostate Cancer More Accurately Than Doctors
The AI tool can detect prostate cancer with 84% accuracy, compared to doctors' 67% accuracy, according to UCLA research.
Study Shows Physician Recommendations Drive Prostate Cancer Treatment Decisions
“This highlights a need for physicians to better integrate patient preferences into their treatment recommendations," says Jonathan Bergman, MD, MPH.
PSMA Response May Indicate Better Metastasis Control in Oligometastatic Castration-Sensitive Prostate Cancer
PSMA response was linked to improved metastasis-free survival in patients with oligometastatic castration-sensitive prostate cancer.